GENSF Stock Chart & Stats
$29.66
$0.00(0.00%)
At close: 4:00 PM EDT
$29.66
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$25.41 - $41.20
Previous CloseN/A
Volume25.00
Average Volume (3M)N/A
Market Cap
$2.07B
Enterprise Value$1.96K
Total Cash (Recent Filing)$43.40M
Total Debt (Recent Filing)$260.70M
Price to Earnings (P/E)31.9
Beta0.39
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.34%
Share Statistics
EPS (TTM)0.72
Shares Outstanding66,540,760
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.83
Price to Sales (P/S)2.00
P/FCF Ratio27.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.24Price Target Upside28.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.01
Revenue Forecast (FY)$9.24M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth indicates expanding adoption of Genus' genetics and services across key markets. Recurring sales of breeding stock and genetic material create predictable topline streams, supporting investment in R&D and scale advantages that tend to persist over multi‑quarter horizons.
Diversified Genetics PlatformDual-segment exposure to both porcine and bovine genetics provides revenue diversification and cross‑market scale benefits. Long-term contracts, repeat purchases for herd refreshment, and value‑added services (selection, reproductive support) strengthen durable recurring revenue and barriers to entry.
Solid Capital StructureA moderate debt position and stable equity ratio give Genus financial flexibility to fund R&D, acquisitions, or withstand livestock market shocks. Positive ROE and a balanced leverage approach support sustainable investment in genetics development without excessive refinancing risk.
Bears Say
Volatile Free Cash FlowIrregular free cash flow limits predictability of capital allocation and can constrain sustained R&D spending, dividend policy or debt reduction. Over multiple quarters this volatility raises the chance that strategic initiatives are delayed or financed at unfavorable terms.
Relatively Low Net MarginDespite strong gross margins, a low net margin implies operating costs, R&D, or other expenses materially compress bottom‑line returns. If persistent, this reduces internal cash generation and limits the company's ability to convert revenue growth into durable earnings expansion.
Exposure To Biosecurity & CyclicalityGenus’ revenue depends on livestock herd health and sector cycles; disease outbreaks, biosecurity shocks or cyclical commodity swings can reduce herd sizes and breeding purchases. These structural industry risks can cause multi‑period revenue and margin volatility.
Genus plc News
GENSF FAQ
What was Genus PLC’s price range in the past 12 months?
Genus PLC lowest stock price was $25.41 and its highest was $41.20 in the past 12 months.
What is Genus PLC’s market cap?
Genus PLC’s market cap is $2.07B.
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Sep 10, 2026 which is in 13 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Feb 26, 2026. The company reported $0.815 earnings per share for the quarter, beating the consensus estimate of $0.608 by $0.207.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC pays a Semiannually dividend of $0.15 which represents an annual dividend yield of 1.34%. See more information on Genus PLC dividends here
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 66,540,760 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of $0.815 in its last earnings report, beating expectations of $0.608. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in GENSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genus plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.24 (28.94% Upside)
$38.24 (28.94% Upside)
Blogger Sentiment
Bullish
GENSF Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $68.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.28%
12-Months-Change
Fundamentals
Return on Equity
1.34%
Trailing 12-Months
Asset Growth
-6.55%
Trailing 12-Months
Company Description
Genus PLC
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
GENSF Stock 12 Month Forecast
Average Price Target
$38.24
▲(28.94% Upside)
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Oxford Nanopore Technologies PLC
―
Ownership Overview
0.26% Insiders
9.77% Mutual Funds
― Other Institutional Investors
82.11% Public Companies and
Individual Investors